CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2014 - 2018)

CytomX Therapeutics (CTMX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $1.1 million in Q4 2018.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.1 million (changed N/A YoY) and the FY2018 annual result came in at $1.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability rose to $1.1 million in Q4 2018, from $520000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2018 to a low of $499000.0 in Q4 2014.
• A 5-year average of $570181.8 and a median of $513000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 5.07% in 2017, down 0.78% in 2017.
• Tracing CTMX's Non-Current Deferred Tax Liability over 5 years: stood at $499000.0 in 2014, then gained by 1.6% to $507000.0 in 2015, then climbed by 1.18% to $513000.0 in 2016, then increased by 1.36% to $520000.0 in 2017, then surged by 118.65% to $1.1 million in 2018.
• The last three Non-Current Deferred Tax Liability figures came in at $1.1 million (Q4 2018), $520000.0 (Q3 2017), and $539000.0 (Q2 2017), per Business Quant data.